This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Performance you can trust hero banner image

EYLEA® (aflibercept) 8 mg

Dosing

TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

Flexible posology with Q4 to Q24 dosing for nAMD/DMO and Q4 to Q20 dosing in RVO

 

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

Download dosing diagrams here
Dosing diagram_tx-naive

EYLEA 8 mg offers a flexible posology with Q4 to Q24 dosing for nAMD/DMO and Q4 to Q20 dosing in RVO.

Dosing diagram for illustrative purposes only.

Dosing diagram_switch

EYLEA 8 mg offers a flexible posology with Q4 to Q24 dosing for nAMD/DMO and Q4 to Q20 dosing in RVO.

Dosing diagram for illustrative purposes only.

*If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician’s discretion. The shortest interval between 2 injections is 1 month. The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion. For full details of posology and situations in which treatment should be withheld see the EYLEA® 114.3 mg/mL Summary of Product Characteristics.

Hear from patients on what the impact of fewer injections means for them

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA 8 mg logo
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-3129, March 2026
EYLEA 8 mg MoA page content card
EYLEA® (aflibercept) 8 mg MoA
Learn more about the MoA (mechanism of action) of EYLEA® (aflibercept) 8 mg
PP-EYL-GB-3080, March 2026
EYLEA 8 mg PFS page content card
EYLEA® (aflibercept) 8 mg Pre-filled Syringe
Access resources for the EYLEA® (aflibercept) 8 mg Pre-filled Syringe
PP-EYL-GB-3078, March 2026

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion. T&E, treat and extend. VEGF, vascular endothelial growth factor.

PP-EYL-GB-3073 | February 2026

    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.